fbpx
QQQ
+ 0.00
314.14
+ 0%
DIA
+ 0.00
308.78
+ 0%
SPY
+ 0.00
380.01
+ 0%
TLT
+ 0.00
143.12
+ 0%
GLD
+ 0.00
161.84
+ 0%

Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week

December 7, 2020 12:29 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week

Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelics Industry News Stories for the Week of November 30th – December 6th, 2020.

Without further ado, let’s get started.

Yahoo Finance readers, please click here to view the full article.

10. Historic Week for Cannabis Legalization in America as House Approves MORE Act

The Comprehensive Reform Bill Would Officially Bring an End to America’s Long-Standing Marijuana Prohibition

On Friday, the U.S. House of Representatives held a historic floor vote, which saw the Marijuana Opportunity, Reinvestment and Expungement (MORE) Act approved in a decisive 228 to 164 vote.

READ FULL CANNABIS LEGALIZATION ARTICLE

9. Oregon Governor Takes First Step to Regulate Psilocybin Mushroom Therapy By Forming New Board

Oregon Became the First State to Legalize Psilocybin Mushrooms for Therapeutic Purposes Last Month

Now the Oregon governor is taking initial steps to launch the program by accepting applications for members of an advisory board tasked with figuring out how to best regulate access to the Psychedelic treatment.

READ FULL OREGON PSILOCYBIN ARTICLE

8. Red White & Bloom Sees 300% Q3 Revenue Growth, Monster Q4 Expected with New Cash Cow Acquisitions Included

In the Third-Quarter, Red White & Bloom Reported Quarter Over Quarter Revenue Growth of More Than 300% and a 69% Gross Margin Before Fair Value Impacts

Considering Red White & Bloom’s (OTCQX:RWBYF) Q3 results included only a couple of weeks worth of Platinum Vape sales and zero PharmaCo revenue, investors and analysts are already salivating over the blockbuster potential of the company’s Q4 Earnings and the smart money is already getting positioned.

READ FULL RWB ARTICLE

7. Legalizing Therapeutic Access to Psilocybin

Psilocybin Proposed System Looks Like Medical Cannabis System

M109 provides for four different license classes: psilocybin product manufacturers, Psilocybin service center operators, psilocybin service facilitators, and testing laboratories, with the service centers playing the role of the clinics at which all consumption of psilocybin must take place and the facilitators taking the role of the medical supervisors of psilocybin therapy.

READ FULL LEGALIZING PSILOCYBIN ARTICLE

6. CBD Doesn’t Impair Driving, Landmark Study Finds, While THC’s Effects Fade in Hours

Small Doses of CBD Appear to Have No Significant Impact on Driving, According to First-of-its-Kind Research Published in the Journal of the American Medical Association

Similar doses of THC, meanwhile, were associated with short-term impairment “modest in magnitude and similar to that seen in drivers with a 0.05%” blood alcohol concentration, the study found. After about four hours, signs of marijuana impairment faded.

READ FULL CBD/THC STUDY ARTICLE

5. Bill to Legalize Marijuana in Mexico Advancing in Committees Ahead of Final Floor Vote

The Body’s Justice, Health, Human Rights and Budget and Public Accounts Committees Are All Taking up the Cannabis Reform Bill

A bill to legalize Marijuana nationwide in Mexico is getting hearings in multiple committees of the Chamber of Deputies on Friday and Saturday following its approval in the Senate last month.

READ FULL MEXICO CANNABIS ARTICLE

4. UK Government Set for Psychedelics Investment Windfall

State-Backed Investor Poised for Seven-Figure Payout as London Drugmaker Prepares Canada Listing

The UK government is on track for a seven-figure windfall from an investment in a Psychedelic drugs company that is readying a float on the Toronto stock exchange. State-backed investor Angel CoFund holds a 5.5% stake in London-based Small Pharma, which has announced its intention to list via a reverse takeover through the Canadian capital pool company Unilock Capital Corp.

READ FULL UK PSYCHEDELICS ARTICLE

3. United Nations Approves WHO Recommendation to Reschedule Cannabis in Historic Vote

The UN Commission on Narcotic Drugs (CND) Accepted a World Health Organization (WHO) Recommendation to Remove Cannabis and Resin From Schedule IV of the 1961 Single Convention on Narcotic Drugs

The historic vote in Vienna could have far-reaching implications for the global medical cannabis industry, ranging from regulatory oversight to scientific research into the plant and its use as a medicine. The eagerly awaited approval of Recommendation 5.1 had a slim majority in favor with 27 votes for, one abstention and 25 votes against.

READ FULL WHO CANNABIS ARTICLE

2. Psychedelic Drugs, Like MDMA Are Showing Signs of Helping with Mental Health Issues

Psychedelic Medicine Could Soon Revolutionize Mental Health

After all, “Traditional medicines that are treating things like depression, addiction, and anxiety really are seeking to numb and mask the issues that surround these illnesses. So, things like Xanax, while they might make you feel better, they can also be highly addictive and are not dealing with the underlying problem,” stated MindMed (OTCQB:MMEDF) co-founder and co-CEO JR Rahn. In addition, clinical studies by New York University and Johns Hopkins are pointing to positive mental health results.

READ FULL PSYCHEDELIC MEDICINE ARTICLE

1. Lawmakers and Advocates React to Federal Marijuana Legalization Bill’s House Passage

The MORE Act, Which Cleared the Chamber in a Decisive 228-164 Vote, Would Federally Deschedule Marijuana

The House on Friday passed a historic bill to federally legalize marijuana, eliciting cheers from pro-reform lawmakers and advocates, and scorn from opponents.

READ FULL MARIJUANA LEGALIZATION ARTICLE

Image by NickyPe from Pixabay